PMID- 29025586
OWN - NLM
STAT- MEDLINE
DCOM- 20171030
LR  - 20171030
IS  - 2210-7762 (Print)
VI  - 216-217
DP  - 2017 Oct
TI  - Prognostic classification of MDS is improved by the inclusion of FISH panel 
      testing with conventional cytogenetics.
PG  - 120-127
LID - S2210-7762(17)30327-7 [pii]
LID - 10.1016/j.cancergen.2017.05.004 [doi]
AB  - Cytogenetics is a critical independent prognostic factor in myelodysplastic 
      syndromes (MDS). Conventional cytogenetics (CC) and Fluorescence in situ 
      hybridization (FISH) Panel Testing are extensively used for the prognostic 
      stratification of MDS, although the FISH test is not yet a bona fide component of 
      the International Prognostic Scoring System (IPSS). The present study compares 
      the utility of CC and FISH to detect chromosomal anomalies and in prognostic 
      categorization. GTG-Banding and FISH Panel Testing specifically for -5/-5q, 
      -7/-7q, +8 and -20q was performed on whole blood or bone marrow samples from 136 
      patients with MDS. Chromosomal anomalies were found in 40 cases by CC, including 
      three novel translocations. FISH identified at least one anomaly in 54/136 
      (39.7%) cases. More than one anomaly was found in 18/54 (33.3%) cases, therefore, 
      overall FISH identified 75 anomalies of which 32 (42.6%) were undetected by CC. 
      FISH provided additional information in cases with CC failure and in cases with a 
      normal karyotype. Further, in ten cases with an abnormal karyotype, FISH could 
      identify additional anomalies, increasing the number of abnormalities per 
      patient. Although CC is the gold standard in the cytogenetic profiling of MDS, 
      FISH has proven to be an asset in identifying additional abnormalities. The 
      number of anomalies per patient can predict the prognosis in MDS and hence, FISH 
      contributed towards prognostic re-categorization. The FISH Panel testing should 
      be used as an adjunct to CC, irrespective of the adequacy of the number of 
      metaphases in CC, as it improves the prognostic classification of MDS.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Kokate, Prajakta
AU  - Kokate P
AD  - Cytogenetics division, SRL Diagnostic Ltd., Prime Square Building, Gaiwadi 
      Industrial Estate, S.V.Road, Goregaon, Mumbai 400 062, India.
FAU - Dalvi, Rupa
AU  - Dalvi R
AD  - Cytogenetics division, SRL Diagnostic Ltd., Prime Square Building, Gaiwadi 
      Industrial Estate, S.V.Road, Goregaon, Mumbai 400 062, India.
FAU - Koppaka, Neeraja
AU  - Koppaka N
AD  - Cytogenetics division, SRL Diagnostic Ltd., Prime Square Building, Gaiwadi 
      Industrial Estate, S.V.Road, Goregaon, Mumbai 400 062, India.
FAU - Mandava, Swarna
AU  - Mandava S
AD  - Cytogenetics division, SRL Diagnostic Ltd., Prime Square Building, Gaiwadi 
      Industrial Estate, S.V.Road, Goregaon, Mumbai 400 062, India. Electronic address: 
      swarna@srl.in.
LA  - eng
PT  - Journal Article
DEP - 20170816
PL  - United States
TA  - Cancer Genet
JT  - Cancer genetics
JID - 101539150
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Bone Marrow/pathology
MH  - Chromosome Banding
MH  - Cytogenetics/*methods
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Karyotyping
MH  - Male
MH  - Middle Aged
MH  - Myelodysplastic Syndromes/*diagnosis/*genetics
MH  - Prognosis
OTO - NOTNLM
OT  - Fluorescence in situ hybridization
OT  - conventional cytogenetics
OT  - myelodysplastic syndrome
EDAT- 2017/10/14 06:00
MHDA- 2017/10/31 06:00
CRDT- 2017/10/14 06:00
PHST- 2016/09/14 00:00 [received]
PHST- 2017/01/06 00:00 [revised]
PHST- 2017/05/24 00:00 [accepted]
PHST- 2017/10/14 06:00 [entrez]
PHST- 2017/10/14 06:00 [pubmed]
PHST- 2017/10/31 06:00 [medline]
AID - S2210-7762(17)30327-7 [pii]
AID - 10.1016/j.cancergen.2017.05.004 [doi]
PST - ppublish
SO  - Cancer Genet. 2017 Oct;216-217:120-127. doi: 10.1016/j.cancergen.2017.05.004. 
      Epub 2017 Aug 16.